Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)
National Institutes of Health
Want a reminder before this closes?
We'll email you 3 days before the deadline. One email, then we stop.
Free. Verify your email, then we send one reminder only.
- Posted
- Feb 12, 2026
- Amount
- $2,500,000
- Closes
- Oct 10, 2028 (in 706 days)
Similar opportunities open now
- Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Nov 2027Up to $1.5M
- Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses May 2028Up to $1M
- Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Nov 19, 2026 (in 15 days)
Classification and identifiers
- Solicitation number
- RFA-NS-28-012
- Assistance listing (CFDA)
- 93.866
Amount
$2,500,000
Who can apply
Small businesses, Local government agencies, Public colleges and universities, and Nonprofits can all apply here. Check the eligibility details below to see if your organization fits.
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
About this opportunity
The National Institutes of Neurological Disorders and Stroke (NINDS) is interested in supporting research projects proposing the optimization and translational development of genomic and biologic therapeutic candidates for Alzheimer’s Disease-Related Dementias (ADRD). Breakthroughs in genomic and biologic therapies are creating new opportunities to treat, prevent, and potentially modify the course of dementias; however, progress is limited by challenges in delivery, safety, manufacturability, and readiness for clinical testing. This program is intended to support projects across the translational pipeline, from optimization through IND development and early clinical evaluation, for genomic and biologic therapeutic candidates with compelling preclinical evidence. Eligible projects may inclu...